News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
US FDA Staff--Schering-Plough Corporation (JOBS) Antipsychotic Works
July 28, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters - Schering-Plough Corp's (SGP.N) experimental antipsychotic drug Saphris works and appears as safe as other similar medications, U.S. Food and Drug Administration staff said in a memo released on Tuesday.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Approvals
Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
November 19, 2026
·
3 min read
·
Heather McKenzie
Insights
The untapped potential of drug repurposing
November 19, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Approvals
GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy
November 18, 2026
·
2 min read
·
Tristan Manalac
Lung cancer
Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety
November 18, 2026
·
3 min read
·
Annalee Armstrong